
Doximity (DOCS) Stock Forecast & Price Target
Doximity (DOCS) Analyst Ratings
Bulls say
Doximity is well-positioned to continue growing in the HCP digital marketing space, as it has demonstrated strong ability to gain market share and outperform the industry growth. With its diverse product offerings and strong partnerships with medical professionals, pharmaceutical companies, and health systems, Doximity has a strong revenue base and potential for future growth. The company's investments in AI tools and other new technologies show its commitment to remain a leader in the market. While there may be some headwinds in the short term due to uncertainty in the pharmaceutical industry, we believe Doximity's strong fundamentals make it a solid investment option for the future.
Bears say
Doximity is facing increased regulatory uncertainties and slower-than-expected growth, leading to a decrease in its price target to $55. Despite beating revenue and earnings estimates in Q3, the company narrowed its full-year guidance and saw a slowdown in top customers' spending. The competition in the market may also pose a risk to Doximity's future growth and financials.
This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.
Doximity (DOCS) Analyst Forecast & Price Prediction
Start investing in Doximity (DOCS)
Order type
Buy in
Order amount
Est. shares
0 shares